{
    "clinical_study": {
        "@rank": "131089", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Other", 
                "description": "Test Drug (V0498 - A mg) - Reference (Ibuprofen)"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Other", 
                "description": "Reference (Ibuprofen) -  Test drug(V0498 - A mg)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the systemic exposure to ibuprofen after single\n      oromucosal administration of the test product V0498 and single oral administration of a\n      reference product."
        }, 
        "brief_title": "Evaluation and Comparison of Systemic Exposure to Ibuprofen After Single Oromucosal Versus Oral Administrations", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subject aged 18 to 45 years (inclusive),\n\n          -  18.5 < or = Body Mass Index < or = 30 kg/m\u00b2,\n\n          -  Non-smoker for at least 6 months\n\n          -  Subject agreed to be registered in the Belgium national register \"VIP Check\n             International\" for this study participation .\n\n        Exclusion Criteria:\n\n          -  Positive serology for Hepatitis B Virus antigens, Hepatitis C Virus or Human\n             Immunodeficiency Virus 1 or 2 antibodies,\n\n          -  Organic disorder likely to modify absorption, distribution or elimination of the\n             medication,\n\n          -  History of sensitivity to ibuprofen or other NonSteroidal Anti-Inflammatory Drugs\n             (NSAIDs) or to any of the excipients\n\n          -  Subject who has donated blood within the past 3 months,\n\n          -  Subject who has forfeited his freedom by administrative or legal award, or who is\n             under guardianship or who has been admitted in a sanitary or social institution,\n\n          -  Participation in another clinical trial in the previous month or subject still within\n             the exclusion period of a previous clinical trial or is participating in another\n             clinical trial,"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859377", 
            "org_study_id": "V00498 TA 1 01", 
            "secondary_id": "2013-000732-96"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2"
                ], 
                "description": "Single oromucosal administration", 
                "intervention_name": "V0498 - A mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2"
                ], 
                "description": "Single oral administration", 
                "intervention_name": "Ibuprofen", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ibuprofen"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Liege", 
                    "country": "Belgium", 
                    "zip": "B-4000"
                }
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Belgium: Ethics Committee", 
                "Belgium: Federal Agency for Medicinal Products and Health Products"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "11 time points up to 10h after administration"
            }, 
            {
                "measure": "Time of Maximum Concentration", 
                "safety_issue": "No", 
                "time_frame": "11 time points up to 10h after administration"
            }, 
            {
                "measure": "Area Under Curve (AUC0-72)", 
                "safety_issue": "No", 
                "time_frame": "11 time points up to 10h after administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859377"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pierre Fabre Medicament", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pierre Fabre Medicament", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}